Genetics and epigenetics of NAFLD and NASH: Clinical impact

Mohammed Eslam, Luca Valenti, Stefano Romeo

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Non-alcoholic fatty liver disease (NAFLD) is now recognised as the most common liver disease worldwide. It encompasses a broad spectrum of conditions, from simple steatosis, through non-alcoholic steatohepatitis, to fibrosis and ultimately cirrhosis and hepatocellular carcinoma. A hallmark of NAFLD is the substantial inter-patient variation in disease progression. NAFLD is considered a complex disease trait such that interactions between the environment and a susceptible polygenic host background determine disease phenotype and influence progression. Recent years have witnessed multiple genome-wide association and large candidate gene studies, which have enriched our understanding of the genetic basis of NAFLD. Notably, the I148M PNPLA3 variant has been identified as the major common genetic determinant of NAFLD. Variants with moderate effect size in TM6SF2, MBOAT7 and GCKR have also been shown to have a significant contribution. The premise for this review is to discuss the status of research into important genetic and epigenetic modifiers of NAFLD progression. The potential to translate the accumulating wealth of genetic data into the design of novel therapeutics and the clinical implementation of diagnostic/prognostic biomarkers will be explored. Finally, personalised medicine and the opportunities for future research and challenges in the immediate post genetics era will be illustrated and discussed.

Original languageEnglish
Pages (from-to)268-279
JournalJournal of Hepatology
Volume68
Issue number2
DOIs
Publication statusPublished - 2018

Fingerprint

Epigenomics
Disease Progression
Fibrosis
Precision Medicine
Genetic Association Studies
Fatty Liver
Non-alcoholic Fatty Liver Disease
Liver Diseases
Hepatocellular Carcinoma
Biomarkers
Genome
Phenotype
Research

Keywords

  • Epigenetics
  • Genetic variation
  • Non-alcoholic fatty liver disease
  • PNPLA3
  • Steatohepatitis

ASJC Scopus subject areas

  • Hepatology

Cite this

Genetics and epigenetics of NAFLD and NASH : Clinical impact. / Eslam, Mohammed; Valenti, Luca; Romeo, Stefano.

In: Journal of Hepatology, Vol. 68, No. 2, 2018, p. 268-279.

Research output: Contribution to journalArticle

Eslam, Mohammed ; Valenti, Luca ; Romeo, Stefano. / Genetics and epigenetics of NAFLD and NASH : Clinical impact. In: Journal of Hepatology. 2018 ; Vol. 68, No. 2. pp. 268-279.
@article{5151e06c84d9497e9cdab1535642f4df,
title = "Genetics and epigenetics of NAFLD and NASH: Clinical impact",
abstract = "Non-alcoholic fatty liver disease (NAFLD) is now recognised as the most common liver disease worldwide. It encompasses a broad spectrum of conditions, from simple steatosis, through non-alcoholic steatohepatitis, to fibrosis and ultimately cirrhosis and hepatocellular carcinoma. A hallmark of NAFLD is the substantial inter-patient variation in disease progression. NAFLD is considered a complex disease trait such that interactions between the environment and a susceptible polygenic host background determine disease phenotype and influence progression. Recent years have witnessed multiple genome-wide association and large candidate gene studies, which have enriched our understanding of the genetic basis of NAFLD. Notably, the I148M PNPLA3 variant has been identified as the major common genetic determinant of NAFLD. Variants with moderate effect size in TM6SF2, MBOAT7 and GCKR have also been shown to have a significant contribution. The premise for this review is to discuss the status of research into important genetic and epigenetic modifiers of NAFLD progression. The potential to translate the accumulating wealth of genetic data into the design of novel therapeutics and the clinical implementation of diagnostic/prognostic biomarkers will be explored. Finally, personalised medicine and the opportunities for future research and challenges in the immediate post genetics era will be illustrated and discussed.",
keywords = "Epigenetics, Genetic variation, Non-alcoholic fatty liver disease, PNPLA3, Steatohepatitis",
author = "Mohammed Eslam and Luca Valenti and Stefano Romeo",
year = "2018",
doi = "10.1016/j.jhep.2017.09.003",
language = "English",
volume = "68",
pages = "268--279",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier B.V.",
number = "2",

}

TY - JOUR

T1 - Genetics and epigenetics of NAFLD and NASH

T2 - Clinical impact

AU - Eslam, Mohammed

AU - Valenti, Luca

AU - Romeo, Stefano

PY - 2018

Y1 - 2018

N2 - Non-alcoholic fatty liver disease (NAFLD) is now recognised as the most common liver disease worldwide. It encompasses a broad spectrum of conditions, from simple steatosis, through non-alcoholic steatohepatitis, to fibrosis and ultimately cirrhosis and hepatocellular carcinoma. A hallmark of NAFLD is the substantial inter-patient variation in disease progression. NAFLD is considered a complex disease trait such that interactions between the environment and a susceptible polygenic host background determine disease phenotype and influence progression. Recent years have witnessed multiple genome-wide association and large candidate gene studies, which have enriched our understanding of the genetic basis of NAFLD. Notably, the I148M PNPLA3 variant has been identified as the major common genetic determinant of NAFLD. Variants with moderate effect size in TM6SF2, MBOAT7 and GCKR have also been shown to have a significant contribution. The premise for this review is to discuss the status of research into important genetic and epigenetic modifiers of NAFLD progression. The potential to translate the accumulating wealth of genetic data into the design of novel therapeutics and the clinical implementation of diagnostic/prognostic biomarkers will be explored. Finally, personalised medicine and the opportunities for future research and challenges in the immediate post genetics era will be illustrated and discussed.

AB - Non-alcoholic fatty liver disease (NAFLD) is now recognised as the most common liver disease worldwide. It encompasses a broad spectrum of conditions, from simple steatosis, through non-alcoholic steatohepatitis, to fibrosis and ultimately cirrhosis and hepatocellular carcinoma. A hallmark of NAFLD is the substantial inter-patient variation in disease progression. NAFLD is considered a complex disease trait such that interactions between the environment and a susceptible polygenic host background determine disease phenotype and influence progression. Recent years have witnessed multiple genome-wide association and large candidate gene studies, which have enriched our understanding of the genetic basis of NAFLD. Notably, the I148M PNPLA3 variant has been identified as the major common genetic determinant of NAFLD. Variants with moderate effect size in TM6SF2, MBOAT7 and GCKR have also been shown to have a significant contribution. The premise for this review is to discuss the status of research into important genetic and epigenetic modifiers of NAFLD progression. The potential to translate the accumulating wealth of genetic data into the design of novel therapeutics and the clinical implementation of diagnostic/prognostic biomarkers will be explored. Finally, personalised medicine and the opportunities for future research and challenges in the immediate post genetics era will be illustrated and discussed.

KW - Epigenetics

KW - Genetic variation

KW - Non-alcoholic fatty liver disease

KW - PNPLA3

KW - Steatohepatitis

UR - http://www.scopus.com/inward/record.url?scp=85033218466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033218466&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2017.09.003

DO - 10.1016/j.jhep.2017.09.003

M3 - Article

AN - SCOPUS:85033218466

VL - 68

SP - 268

EP - 279

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 2

ER -